Pulmonary Fibrosis Breakthrough News Features Dr. Murali Ramaswamy
Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible form of interstitial lung disease (ILD). It is estimated that there are between 50,000 and 70,000 patients living with IPF in the United States, and the disease typically affects people aged 50 and older. Until recently, there was no definitive treatment, short of lung transplant, for IPF, according to myfox8, House Calls, Morning Show news that features Dr. Ramaswamy.
However, just this month, the FDA approved two new medications, pirfenidone and nintedanib, that help slow the progression of IPF. Learn more from Dr. Ramaswamy during his interview on myfox8, House Calls, Morning Show news .